Morria Biopharmaceuticals Plc. Announces Initiation Of Its Phase II Study In Contact Dermatitis Patients Using MRX6, A Novel Anti-Inflammatory Drug

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today the initiation of its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6. The double-blind, placebo-controlled study of up to 80 contact dermatitis patients will take place at the Hadassah Hospital in Israel. A previous pilot clinical study demonstrated that a topical preparation of MRX6, applied twice daily for 28 days, scored 69% improvement based on conventional Physician's Assessment versus a standard 30% placebo effect generated by the vehicle. The upcoming study will examine a shortened b.i.d regime of 21 days as well as look at pharmacokinetics and dose-response parameters.


"This is our latest positive news in the clinical development of our unique and novel products" said Yuval Cohen, President of Morria. "We look forward to reporting the results of the phase II study and partnering with a company for the marketing of MRX6".


About Contact Dermatitis


Contact dermatitis is an allergic condition in which patients develop skin reactions when coming into contact with certain materials/substances such as metals, latex and fabrics. The market for this condition is estimated at $600m.


Source

Morria Biopharmaceuticals Plc